Salarius Pharmaceuticals (Salarius Pharmaceuticals) EBIT : $-12.90 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals EBIT?

Salarius Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-0.97 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.90 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Salarius Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -866.96%. Salarius Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Salarius Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 397.38%.

Salarius Pharmaceuticals EBIT Historical Data

The historical data trend for Salarius Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals EBIT Chart

Salarius Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-8.26

-7.61

-12.81

-22.98

-12.90

Salarius Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-6.48	-5.42	-3.97	-2.53	-0.97

Competitive Comparison of Salarius Pharmaceuticals's EBIT

For the Biotechnology subindustry, Salarius Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Salarius Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Salarius Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Salarius Pharmaceuticals's EV-to-EBIT falls into.

Salarius Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.90 Mil.

Salarius Pharmaceuticals (NAS:SLRX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Salarius Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-3.884 * ( 1 - 0% )	/	( (0.54	+	0.356)	/ 2 )
=	-3.884	/	0.448
=	-866.96 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.404	-	1.861	-	( 7.581	-	max(0, 2.321	-	8.324	+	7.581	))
=	0.54

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.587	-	1.01	-	( 5.9	-	max(0, 1.299	-	6.52	+	5.9	))
=	0.356

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Salarius Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.884	/	( ( (0 + max(-1.119, 0))	+	(0 + max(-0.389, 0)) )	/	2 )
=	-3.884	/	( ( 0	+	0 )	/	2 )
=	-3.884	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.743)	-	(1.861	+	0	+	0.0010000000000003)
=	-1.119

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.62)	-	(1.01	+	0	+	-0.0010000000000001)
=	-0.389

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Salarius Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-12.895	/	-3.245
	=	397.38 %

Salarius Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (NAS:SLRX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

FP1:Germany

Address

2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021

Website

https://www.salariuspharma.com

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Executives

Tess Burleson	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan I Lieber	director	C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
William K. Mcvicar	director	C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421
Arnold C Hanish	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Mark J Rosenblum	officer: Exec VP Finance, Interim CFO	3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244
David J. Arthur	director, officer: Chief Executive Officer	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Scott Jordan	officer: Chief Financial Officer	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Mccreedy Bruce J Jr.	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan P Northrup	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Pao-yu Chuang	officer: Controller	2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021
Paul Lammers	director	2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Boston Foundation, Inc.	10 percent owner	75 ARLINGTON STREET, BOSTON MA 02116
Christoph H Westphal	10 percent owner	C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142
Longwood Fund Ii, L.p.	10 percent owner	800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199
Roger D Tung	director	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421